Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,230.12
(
0.29%
)
US TECH 100
26,942.00
(
0.87%
)
Dow Jones
49,499.27
(
-0.31%
)
Brent Oil
107.80
(
0.00%
)
Bitcoin
78,187.87
(
-0.01%
)
News Focus
News Focus
Post# of 257483
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122925
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 230917

Thursday, 02/01/2024 6:15:43 PM

Thursday, February 01, 2024 6:15:43 PM

Post# of 257483
NRBO’s DA-1726 GLP-1/glucagon agent to start phase-1 in 1H24:

https://finance.yahoo.com/news/neurobo-pharmaceuticals-announces-fda-clearance-130100854.html

NeuroBo Pharmaceuticals...today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR). The company plans to initiate a Phase 1 clinical trial, for the treatment of obesity, in the first half of this year.

The stock was +67% today on this announcement!?

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today